The FDA approved the targeted therapy enasidenib for patients with refractory or relapsed acute myeloid leukemia with mutant IDH2. The drug produces remissions in some patients and may reduce the need for blood transfusions, although researchers acknowledge that the FDA's approval came with less supporting evidence than usual.
from Cancer via ola Kala on Inoreader http://ift.tt/2wuhJog
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου